-
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 1)
Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from…
-
ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some…
-
ASH 2024 | Dr. He Huang’s Team Advances Breakthroughs in Bone Marrow Transplantation and Cellular Immunotherapy
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts leading global experts to discuss groundbreaking research and advancements. This year, Dr. He Huang’s team from the Bone…
-
ASH 2024 | Dr. Qian Jiang in Conversation with Dr. Jun Zhu on Leukemia Updates from Day One of ASH 2024
The 2024 Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10 in San Diego, USA. As one of the foremost global gatherings in the field of hematology, this prestigious conference attracted the attention of clinicians and researchers worldwide, including a keen audience from China. To bring the latest…
-
ASH 2024 | Dr. Huafeng Wang’s Team Shines with Four Groundbreaking Studies on MDS Therapies and AML Innovations
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7 to 10, 2024, in San Diego, USA. Renowned as the largest international academic event in hematology, the conference showcased cutting-edge research and the latest advancements in drug development, representing the highest academic standards in the field. At this prestigious…
-
AASLD Exclusive Interview with Dr. Grace Lai-Hung Wong: Quantitative HBsAg – A New Perspective in Advancing Hepatitis B Management and Functional Cure
Understanding the Significance of Quantitative HBsAg Hepatology Digest: In your presentation, you discussed the quantification of HBsAg. How does it contribute to understanding HBV infection and disease progression? Dr. Grace…
-
ASH 2024 | Dr. Erlie Jiang: Elevated rhTPO Dosing Accelerates Platelet Engraftment and Reduces aGVHD in Allo-HSCT
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay…
-
ASH 2024 | Dr. Mingfeng Zhao: Pursuing Innovation—iCAR-T Therapy Offers New Hope for AML Treatment
Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10,…
Connecting Medical Expertise through Media